About Neurogene Inc.
https://www.neurogene.comNeurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
CEO
Rachel L. McMinn
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-12-19 | Reverse | 1:4 |
| 2023-09-25 | Reverse | 1:5 |
ETFs Holding This Stock
VTS.AX
Weight:0.00%
Shares:438.78K
IWM
Weight:0.01%
Shares:235.95K
XSU.TO
Weight:0.01%
Shares:235.95K
Summary
Showing Top 3 of 64
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
SAMSARA BIOCAPITAL, LLC
Shares:1.72M
Value:$32.28M
BLACKROCK INC.
Shares:1.39M
Value:$26.22M
RTW INVESTMENTS, LP
Shares:1.36M
Value:$25.61M
Summary
Showing Top 3 of 93
About Neurogene Inc.
https://www.neurogene.comNeurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $23.8M ▼ | $-20.95M ▲ | 0% | $-0.99 ▲ | $-20.18M ▲ |
| Q2-2025 | $0 | $26.08M ▲ | $-22.02M ▲ | 0% | $-1.05 ▲ | $-21.25M ▲ |
| Q1-2025 | $0 | $25.92M ▲ | $-22.65M ▼ | 0% | $-1.08 ▲ | $-21.88M ▼ |
| Q4-2024 | $0 | $6.17M ▼ | $-19.51M ▲ | 0% | $-1.31 ▼ | $-20.71M ▼ |
| Q3-2024 | $0 | $22.18M | $-20.22M | 0% | $-1.19 | $-19.41M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $265.41M ▼ | $287.83M ▼ | $22.29M ▼ | $265.54M ▼ |
| Q2-2025 | $274.52M ▼ | $297.32M ▼ | $24.06M ▲ | $273.25M ▼ |
| Q1-2025 | $292.6M ▼ | $315.3M ▼ | $23.51M ▼ | $291.8M ▼ |
| Q4-2024 | $312.4M ▲ | $335.73M ▲ | $25.36M ▼ | $310.38M ▲ |
| Q3-2024 | $138.99M | $164.12M | $26.71M | $137.41M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-20.95M ▲ | $-19.68M ▼ | $22.44M ▲ | $9.86M ▲ | $12.19M ▲ | $-19.81M ▼ |
| Q2-2025 | $-22.02M ▲ | $-19.46M ▲ | $7.45M ▲ | $54K ▲ | $-11.96M ▲ | $-19.61M ▲ |
| Q1-2025 | $-22.65M ▼ | $-20.77M ▼ | $-45.05M ▲ | $4K ▼ | $-65.81M ▼ | $-21.55M ▼ |
| Q4-2024 | $-19.51M ▲ | $-17.5M ▼ | $-102.62M ▼ | $190.06M ▲ | $69.95M ▲ | $-17.61M ▼ |
| Q3-2024 | $-20.22M | $-15.56M | $-28.97M | $131K | $-44.4M | $-15.73M |
CEO
Rachel L. McMinn
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-12-19 | Reverse | 1:4 |
| 2023-09-25 | Reverse | 1:5 |
ETFs Holding This Stock
VTS.AX
Weight:0.00%
Shares:438.78K
IWM
Weight:0.01%
Shares:235.95K
XSU.TO
Weight:0.01%
Shares:235.95K
Summary
Showing Top 3 of 64
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
SAMSARA BIOCAPITAL, LLC
Shares:1.72M
Value:$32.28M
BLACKROCK INC.
Shares:1.39M
Value:$26.22M
RTW INVESTMENTS, LP
Shares:1.36M
Value:$25.61M
Summary
Showing Top 3 of 93